Tresiba Overdose and Accidental Excess Dose: What to Do and What Clinicians Should Know

Insulin degludec (brand name Tresiba, U-100 and U-200 formulations) is an ultra-long-acting basal insulin approved by the FDA for adults and children with diabetes who need once-daily background insulin coverage. It is not the same molecule as insulin glargine (Lantus, Toujeo, Basaglar) or NPH insulin, and its overdose behavior is different from both because of how it is absorbed from the injection site.

The core issue with a Tresiba overdose is duration, not intensity. Because insulin degludec forms a subcutaneous depot that releases insulin slowly for well beyond 24 hours, an accidental excess dose does not behave like a short-acting insulin overdose that peaks and resolves within a few hours. Hypoglycemia can recur in waves over roughly one to two days even after blood glucose is corrected, which is why single-episode treatment is not enough and extended monitoring is the defining feature of safe management. There is no antidote for any insulin overdose; care is entirely supportive, built on glucose replacement that outpaces ongoing insulin absorption.

This article describes what is established about degludec's pharmacology and general hypoglycemia management, what is plausible from the drug's known mechanism but not separately proven in overdose-specific trials, and what a clinician or caregiver should verify locally (poison control, current FDA labeling, institutional protocol) before acting on a specific dose or number.

Why a Tresiba overdose behaves differently from other insulin overdoses

Insulin degludec is formulated so that after subcutaneous injection it forms long chains of insulin hexamers in the tissue. These chains slowly break down into smaller units that enter the bloodstream over an extended period, producing the flat, low-variability profile that makes degludec useful as a once-daily basal insulin. In an overdose, the same mechanism works against the patient: a larger depot forms, more insulin is released per hour, and the glucose-lowering effect is both stronger and longer than a comparable overdose of a shorter-acting basal insulin.

Insulin glargine has a shorter duration of action, and NPH insulin has a distinct peak and is largely cleared within a day. Overdoses of those insulins still require caution, but clinicians can generally bracket the risk window with more confidence. With degludec, blood glucose can be corrected, appear stable, and then fall again several hours later as the depot continues releasing insulin. This recurrent pattern, rather than the emergency's initial severity, is the main reason degludec overdoses call for a longer observation period than many clinicians default to for other insulins.

Recognizing an insulin degludec overdose

Overdose symptoms are hypoglycemia symptoms. They typically progress in a predictable order, though the onset after a degludec overdose can be delayed compared with shorter-acting insulins, especially if the patient ate around the time of injection.

Mild to moderate (roughly 54 to 70 mg/dL): tremor, sweating, palpitations, anxiety, hunger. The patient is alert and can self-treat.

Severe (below roughly 54 mg/dL, or any event requiring help from another person regardless of the number): confusion, slurred speech, visual disturbance, seizure, loss of consciousness. This definition of severe hypoglycemia (dependence on assistance from another person) reflects widely used diabetes-care guidance rather than a single glucose cutoff.

Delayed presentation: because degludec has no pronounced peak, some patients feel normal for one to two hours after an excess dose, particularly after a large meal, before symptoms gradually worsen. This delay can create false reassurance and is a reason not to dismiss an accidental excess dose just because the patient initially feels fine.

What to do immediately after an excess dose

If the patient is conscious and able to swallow

Give 15 to 20 g of fast-acting carbohydrate (glucose tablets, regular juice, or sugar dissolved in water), recheck blood glucose in 15 minutes, and repeat if it remains below 70 mg/dL. This stepwise approach is the standard hypoglycemia response described by the CDC and used broadly in diabetes care (CDC: Low Blood Sugar). The important difference after a degludec overdose is that this cycle may need to repeat multiple times over the following day; a single successful correction does not mean the episode is over.

If the patient is unconscious, seizing, or cannot safely swallow

A caregiver should give glucagon (nasal, 3 mg, or injectable, 1 mg intramuscularly) and call emergency services. Glucagon raises glucose temporarily by releasing stored liver glycogen, with an effect that generally lasts on the order of an hour. Because degludec's glucose-lowering action outlasts glucagon's effect by many hours, glucagon is a bridge to emergency care, not a definitive treatment.

When to involve emergency services regardless of home treatment

• Loss of consciousness or seizure at any point
• Glucose that will not stay above 70 mg/dL after two rounds of oral glucose
• A dose that is a large multiple of what was prescribed (for example, a suspected tenfold dialing error)
• The person lives alone and cannot be reliably monitored for the next day
• Any intentional overdose, regardless of current symptoms

Emergency department and inpatient management

Severe or refractory hypoglycemia is generally treated with intravenous dextrose, followed by a continuous dextrose infusion titrated to keep glucose in a safe range, because oral intake alone often cannot keep pace with an ongoing insulin depot. Exact bolus volumes, concentrations, and infusion targets are institution- and patient-specific; clinicians should follow their own protocol and current poison control or toxicology guidance rather than a fixed number from this article.

Because degludec's effect is prolonged, published clinical experience with ultra-long-acting insulin overdose describes recurrent hypoglycemia extending well beyond the first several hours, which supports monitoring measured in days rather than hours for significant overdoses. The exact outer limit of risk in a specific patient is not something that can be predicted precisely from the dose alone, and clinicians should treat the duration as uncertain rather than fixed.

Patients who required continuous dextrose support, or who presented with seizure or loss of consciousness, generally warrant admission to a unit capable of frequent or continuous glucose monitoring. Patients with a modest excess dose, no neuroglycopenic symptoms, and glucose that stays above 70 mg/dL with oral intake may be candidates for a shorter period of observation, but this decision should be made by the treating clinician based on the specific dose, symptoms, and home support available, not by a fixed rule.

Standard-dose hypoglycemia data does not describe overdose risk

The DEVOTE cardiovascular outcomes trial compared insulin degludec with insulin glargine U100 in people with type 2 diabetes and found degludec was non-inferior for major cardiovascular events, with a secondary finding of lower rates of severe hypoglycemia at standard, correctly prescribed doses. The direction of that finding (less hypoglycemia at therapeutic doses with degludec than with glargine) is well established in the diabetes literature; the exact percentage reductions should be confirmed against the original trial publication before being quoted as a precise figure, since inherited citation details in earlier drafts of this material could not be verified.

This standard-dose safety advantage does not transfer to overdose. A drug that is comparatively gentle on hypoglycemia risk when dosed correctly can still cause severe, prolonged hypoglycemia when the dose is wrong by a large margin. Readers should not interpret degludec's favorable standard-dose profile as reassurance during an overdose event.

Mechanism, in brief

Insulin degludec is a modified human insulin with a fatty acid side chain that promotes both subcutaneous depot formation and albumin binding in the bloodstream, both of which slow its release and extend its duration of action compared with earlier basal insulins. Like all insulins, it binds the insulin receptor on liver, muscle, and fat tissue, suppressing the liver's glucose output and promoting glucose uptake into peripheral tissue. In overdose, this suppression is excessive relative to what the liver and diet can replace, which is why the treatment strategy is to replace glucose faster than the drug is clearing, not to try to remove or reverse the insulin itself. There is no dialysis-based or antidote-based way to remove degludec from the body; hemodialysis is not an effective way to clear insulin.

Special populations

Older adults. Reduced kidney function can prolong insulin clearance, and blunted counter-regulatory hormone responses in older adults mean the warning symptoms (tremor, sweating) that prompt younger patients to eat may be absent or reduced. This raises the risk of progressing directly to confusion or worse without an obvious warning phase.

Patients also taking a sulfonylurea (glipizide, glyburide, others). These drugs stimulate the patient's own insulin secretion. Combined with an exogenous insulin overdose, the total glucose-lowering burden is higher than either drug alone would suggest, and clinicians should account for this when estimating dextrose needs.

Type 1 versus type 2 diabetes. People with type 1 diabetes have no endogenous insulin production to "turn off" as a counter-regulatory mechanism and may have less reliable glycogen stores, which plausibly makes a degludec overdose more severe or prolonged relative to a similar relative excess in someone with type 2 diabetes. This is a reasonable extrapolation from known physiology rather than a finding specific to degludec overdose research.

Preventing accidental overdoses

The most commonly described accidental overdose pattern is a dialing or concentration error: a patient prescribed 10 units dials 100 units, or confusion arises when switching between U-100 and U-200 pens. Both Tresiba concentrations are designed so the pen dials in matching unit increments (the device compensates internally for concentration), which is intended to prevent a twofold dosing error at the pen level. Confusion is more likely if a syringe is used to draw up insulin from a pen cartridge instead of using the pen mechanism as intended, an off-label practice that should be avoided.

Other prevention points worth discussing with a prescriber:

• Never share a Tresiba pen between patients, even with a new needle
• Use a dose log or a pen with dose-memory capability if forgetting whether a dose was taken is a recurring problem
• Ask your prescriber in advance what to do if you accidentally inject more than prescribed, before an event happens, rather than during one

Post-overdose follow-up

After any overdose significant enough to require monitoring beyond a single home correction, glucose checks should continue at a reduced frequency for an additional day after the acute episode resolves, and the prescriber should review what caused the error (pen confusion, vision impairment, cognitive factors, or intentional self-harm) so a dose or device change can be considered. If the overdose was intentional, a psychiatric evaluation and a documented safety plan should be completed before the patient resumes self-administered insulin. Patients discharged after a significant overdose should leave with a glucagon prescription (nasal or injectable) and a household member trained to use it.

Home-treat or emergency-care decision framework

This framework organizes the situation by what changes the recommended action, not by glucose number alone, since the same reading can mean different things depending on symptoms, dose, and who is present.

The recurring theme across every row: a single normal glucose reading after treatment is not evidence that the episode is over. The decision to stop monitoring should be based on sustained normal readings over an extended period, not on one good number.

What is established, what is plausible, and what needs verification

Established: insulin degludec has a longer duration of action than insulin glargine or NPH insulin; there is no antidote for insulin overdose of any kind; management is supportive glucose replacement; the CDC's Rule of 15 is standard first-line treatment for conscious hypoglycemia; glucagon is a temporary bridge whose effect wears off well before degludec's does.

Plausible but not separately proven for overdose specifically: the precise 24-to-48-hour recurrence window described in this article is a reasonable extrapolation from degludec's known pharmacokinetics and from published clinical experience with ultra-long-acting insulin overdose, but it is not a fixed rule that applies identically to every patient or every dose size. The comparative severity in type 1 versus type 2 diabetes during overdose is inferred from general physiology, not from overdose-specific comparative data.

Needs verification before publication: exact numeric details historically attached to this topic (specific PMIDs, exact DEVOTE hypoglycemia reduction percentages, specific IV dextrose bolus volumes and infusion rates, and the FDA label edition and page) should be confirmed against the current, primary sources by the reviewing clinician before this article is finalized. Where a precise number could not be independently verified for this draft, it has been described qualitatively rather than stated as an exact figure.